Proton therapy for oropharyngeal cancer matched standard intensity-modulated radiotherapy (IMRT) in cancer control while showing higher 5-year survival and fewer feeding-tube and dry-mouth problems, according to a phase 3 trial published in The Lancet in January 2026. In this study led by MD Anderson Cancer Center, 5-year overall survival among 440 patients with stage III–IV oropharyngeal cancer was 90.9% with proton therapy and 81.0% with standard treatment. Because squamous cell cancer of the tonsil and tongue base is usually not a main indication for carbon ion therapy in Japan, proton therapy is a valuable option for head and neck patients who were looking into carbon ion therapy in Japan. To find out which treatment fits your stage and tumor type, please use our head and neck radiotherapy eligibility and cost consultation.
What is oropharyngeal cancer, and why proton therapy?
The oropharynx is the area behind the uvula that includes the tonsils, the base of the tongue and the soft palate. Most cancers here are squamous cell carcinomas, and a growing share is linked to human papillomavirus (HPV). HPV-related oropharyngeal cancer responds well to treatment and many patients live for decades, so protecting the ability to eat and speak has become as important as controlling the cancer.
Stage III–IV disease is usually treated with chemotherapy plus radiation given in 33 sessions over about seven weeks. The salivary glands, swallowing muscles and oral mucosa sit right next to the tumor. X-rays keep depositing energy beyond the tumor, while protons release most of their energy at a set depth and stop (the Bragg peak), sharply lowering the dose to the front of the mouth and the opposite salivary gland. See What Is Carbon Ion Therapy? for the basic principle.
Intensity-modulated proton therapy (IMPT) paints the tumor spot by spot with thin proton beams. This trial was the first large randomized comparison of whether it changes survival and quality of life in real patients.
Results of the 440-patient phase 3 trial
From October 2013 to May 2022, more than 20 US institutions randomized 440 patients with stage III–IV oropharyngeal cancer: 221 to proton therapy and 219 to standard IMRT. Both arms received 70 Gy in 33 fractions, and median follow-up was 3.14 years. The results appeared in The Lancet, volume 407 (2026).
| Outcome | Proton (IMPT) | X-ray (IMRT) |
|---|---|---|
| Patients | 221 | 219 |
| 3-year progression-free survival | 82.5% | 83.0% |
| 5-year progression-free survival | 81.3% | 76.2% |
| 5-year overall survival | 90.9% | 81.0% |
| Hazard ratio for death | 0.58 (42% lower risk of death with protons) | |
The primary goal was to show that proton therapy is not worse at controlling cancer (non-inferiority). With 3-year progression-free survival of 82.5% vs 83.0%, that goal was met, and 5-year overall survival was about 10 percentage points higher with protons. The investigators called IMPT "a new standard-of-care treatment option for patients with oropharyngeal cancer."
How much did swallowing, dry mouth and feeding-tube problems decrease?
| Side effect | Proton | X-ray |
|---|---|---|
| Gastrostomy (feeding) tube dependence | 26.8% | 40.2% |
| Swallowing difficulty | 31% | 49% |
| Dry mouth (xerostomia) | 33% | 45% |
| Severe lymphopenia | 76% | 89% |
Feeding-tube dependence fell from four in ten patients to fewer than three in ten, and swallowing difficulty and dry mouth also decreased. Better preservation of lymphocytes, a type of immune cell, is one clue the investigators highlight to explain the survival difference. Mouth soreness, neck skin reactions and taste changes can still occur with protons; they are usually managed with pain relief, oral care and nutrition support and improve within weeks after treatment.
Proton vs carbon ion: which one for oropharyngeal cancer?
In its guidance for overseas patients, Japan's QST Hospital excludes squamous cell cancers of the oral cavity, pharynx and larynx from carbon ion therapy, because they respond well to X-rays and protons. Carbon ions are strongest for radioresistant non-squamous tumors such as adenoid cystic carcinoma, mucosal melanoma and sarcoma — see head and neck carbon ion therapy criteria.
| Item | Proton therapy | Carbon ion therapy |
|---|---|---|
| Oropharyngeal squamous cell cancer | Main option (this phase 3 trial) | Usually not indicated |
| Adenoid cystic carcinoma, mucosal melanoma | Considered case by case | Main indication |
| Chemotherapy | Commonly combined | Depends on tumor type |
| Sessions | About 33 (about 7 weeks) | About 16 (about 4 weeks) |
The first step is to confirm the tumor type: squamous cell cancer points to proton therapy, non-squamous cancer to carbon ion therapy. A general comparison is in carbon ion vs proton therapy.
Proton therapy cost and hospitals in Japan
Japan's public insurance covers proton therapy for head and neck malignancies but excludes squamous cell cancers of the oral cavity, pharynx and larynx. Overseas patients pay the hospital's self-pay price. Published prices:
| Hospital | Category | Price (tax incl.) | Effective |
|---|---|---|---|
| National Cancer Center Hospital East (Kashiwa, Chiba) | Self-pay, adult rare cancers (head and neck, skull base, sarcoma) | JPY 4,500,000 | From Oct 1, 2024 |
| National Cancer Center Hospital East | Advanced Medical Care technical fee | JPY 2,941,000 | As of Apr 2025 |
| University of Tsukuba Hospital Proton Medical Research Center | Self-pay, standard course | JPY 3,506,000 | From Nov 1, 2025 |
These prices cover the proton irradiation only. Consultations, imaging, chemotherapy, hospital stay, accommodation and interpreting are extra, and about seven weeks of treatment means a long stay. Exact totals are confirmed by the hospital's estimate after record review. Compare carbon ion centers on Japanese Institutions.
Wondering whether proton therapy or carbon ion therapy in Japan suits you, and what the total cost would be? Contact us or call +82-2-517-5117.
Documents to prepare
- Pathology report: tumor type (squamous or not) and HPV (p16) status
- Imaging CD (DICOM): recent neck MRI/CT and PET-CT
- Endoscopy photos and findings: tumor site (tonsil, tongue base, soft palate) and extent
- Referral letter: TNM stage and prior surgery, chemotherapy and radiation records
- Current status: swallowing, weight change and dental condition (a dental check is needed before treatment)
FAQ
Is proton therapy better than standard radiation for oropharyngeal cancer?
In the Lancet phase 3 trial, cancer control (3-year progression-free survival) was similar, while 5-year overall survival was 90.9% with protons and 81.0% with standard treatment. Feeding-tube dependence, swallowing difficulty and dry mouth were also lower with protons.
Can oropharyngeal cancer be treated with carbon ion therapy?
Squamous cell oropharyngeal cancer is usually not a carbon ion indication; protons or X-rays are considered first. Non-squamous tumors such as adenoid cystic carcinoma or mucosal melanoma can be reviewed at Japanese carbon ion centers.
How much does proton therapy for oropharyngeal cancer cost in Japan?
For self-pay patients, National Cancer Center Hospital East lists JPY 4,500,000 for head and neck rare cancers (from October 2024) and University of Tsukuba Hospital lists JPY 3,506,000 for a standard course (from November 2025). Tests, chemotherapy and living costs are extra.
How long does treatment take?
The trial gave 70 Gy in 33 sessions, about seven weeks at five sessions a week, plus time for tests and planning.
Related articles
Wondering if carbon ion therapy is possible for you, and what it costs?
We help you prepare consultations with Japanese institutions and provide medical interpreting.
Free consultationCall +82-2-517-5117Sources
- Frank SJ et al. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: phase 3 trial. The Lancet 2026;407:174-184
- ClinicalTrials.gov NCT01893307
- The ASCO Post: IMPT vs IMRT in Oropharyngeal Cancer (January 2026)
- National Cancer Center Hospital East: proton therapy cost and insurance (Japanese)
- National Cancer Center Hospital East: self-pay proton fee revision 2024 (Japanese)
- University of Tsukuba Hospital: proton therapy fee revision, Nov 2025 (Japanese)
- QST Hospital: Information for patients from abroad
General information based on public sources; not a substitute for diagnosis or treatment. Eligibility is decided by the treating physicians. Written by the FTH editorial team.